Table 1.
Characteristics of patients in the study population
| Characteristic | EU5a N = 813 |
France N = 146 |
Germany N = 175 |
Italy N = 173 |
Spain N = 141 |
UK N = 173 |
|---|---|---|---|---|---|---|
| Median age at diagnosis, years (IQR) | 66 (58–74) | 65 (57–73) | 68 (60–74) | 65 (57–72) | 66 (61–74) | 65 (57–75) |
| Male, n (%) | 477 (59) | 83 (57) | 106 (61) | 99 (57) | 85 (60) | 103 (60) |
| SCT during total at-risk period, n (%)b | 317 (39) | 64 (44) | 58 (33) | 73 (42) | 49 (35) | 65 (38) |
| ISS stage at diagnosis, n (%) | ||||||
| 1 | 120 (15) | 22 (15) | 23 (13) | 28 (16) | 27 (19) | 22 (13) |
| 2 | 282 (35) | 46 (32) | 49 (28) | 56 (32) | 58 (41) | 75 (43) |
| 3 | 380 (47) | 74 (51) | 95 (54) | 78 (45) | 51 (36) | 71 (41) |
| Unknown | 31 (4) | 3 (2) | 8 (5) | 11 (6) | 5 (4) | 5 (3) |
| ECOG performance status at 1 L initiation, n (%) | ||||||
| 0 | 138 (17) | 11 (8) | 34 (19) | 43 (25) | 19 (14) | 36 (21) |
| 1 | 467 (57) | 86 (59) | 110 (63) | 84 (49) | 77 (55) | 103 (60) |
| 2 | 181 (22) | 44 (30) | 27 (15) | 43 (25) | 37 (26) | 26 (15) |
| ≥ 3 | 20 (3) | 5 (3) | 3 (2) | 3 (2) | 7 (5) | 2 (1) |
| Unknown | 8 (1) | 0 | 1 (1) | 0 | 1 (1) | 6 (4) |
| Circumstances that led to MM diagnosis, n (%) | ||||||
| Bone pain | 513 (63) | 97 (66) | 109 (62) | 96 (56) | 95 (67) | 111 (64) |
| HC | 174 (21) | 30 (21) | 29 (17) | 30 (17) | 30 (21) | 52 (30) |
| VF | 188 (23) | 37 (25) | 45 (26) | 42 (24) | 22 (16) | 35 (20) |
| OF | 34 (4) | 4 (3) | 6 (3) | 13 (8) | 6 (4) | 6 (4) |
| SCC | 29 (4) | 5 (3) | 4 (2) | 8 (5) | 4 (3) | 7 (4) |
| ≥ 1 bone-related problemc | 634 (78) | 117 (80) | 135 (77) | 128 (74) | 110 (78) | 137 (79) |
| ≥ 1 HC, VF, OF or SCC | 359 (44) | 67 (46) | 71 (41) | 79 (46) | 56 (40) | 79 (46) |
| ≥ 1 VF, OF or SCC | 233 (29) | 45 (31) | 52 (30) | 58 (34) | 30 (21) | 42 (24) |
| Renal impairment | 187 (23) | 29 (20) | 55 (31) | 25 (15) | 26 (18) | 49 (28) |
| Presentation at the initiation of 1 L, n (%) | ||||||
| ≥ 2 bone lesions | 598 (74) | 111 (76) | 138 (79) | 127 (73) | 96 (68) | 118 (68) |
1 L first-line treatment, ECOG Eastern Cooperative Oncology Group, EU5 five European countries (France, Germany, Italy, Spain and the UK), HC hypercalcemia, IQR interquartile range, ISS international staging system, MM multiple myeloma, OF other non-vertebral fracture, SCC spinal cord compression, SCT stem cell transplantation, UK United Kingdom, VF vertebral fracture
aAggregated EU5 data have been weighted based on the MM incidence in each country so base sizes for individual countries may not equal the EU5 total
bOverall study period from MM diagnosis to disease progression following 1 L
cAny of bone pain, HC, VF, OF and SCC